3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
56
Squamous Cell Carcinoma of Head and Neck
31
Lung Neoplasms
17
Head and Neck Neoplasms
17
Urinary Bladder Neoplasms
16
Oropharyngeal Neoplasms
14
Nasopharyngeal Carcinoma
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Carcinoma
10
Small Cell Lung Carcinoma
9
Carcinoma, Squamous Cell
9
Uterine Cervical Neoplasms
8
Pancreatic Neoplasms
8
Ovarian Neoplasms
8
Carcinoma, Transitional Cell
8
Neoplasm Metastasis
7
Mouth Neoplasms
7
Breast Neoplasms
7
Triple Negative Breast Neoplasms
6
Recurrence
6
Neoplasms
6
Mesothelioma, Malignant
6
Melanoma
6
Gallbladder Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Esophageal Neoplasms
6
Colorectal Neoplasms
6
Biliary Tract Neoplasms
6
Medulloblastoma
5
Laryngeal Neoplasms
5
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Non Small Cell Lung Cancer NSCLC
×
Cisplatin
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA